Form D · Pharmaceuticals

HedgePath Pharmaceuticals, Inc.

Tampa, FL · CIK 0001042418

Offering snapshot reported Apr 22, 2016 · SEC filing

Reported sold
$600K
Offering amount: $5.5M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 11, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 22, 2016Initial$600,000No comparison3SEC filing
Jan 15, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Sep 29, 2006PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0 (estimated)
Form D file number
021-261874
The Company may retain FINRA member placement agents and will pay standard market commissions and other compensation to such agents.

Source: Form D, filed Apr 22, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Stefan J. Cross Director
Garrison J. Hasara, Cpa Executive
Frank E. O'donnell, Jr., Md Director, Executive
R. Dana Ono, Md Director
Samuel P. Sears, Jr. Director
Nicholas J. Virca Executive
W. Mark Watson, Cpa Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
324 South Hyde Park Avenue Suite 350
Tampa, FL, 33606